BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA) concerning the Company and its officers’ potential violation of federal securities laws.
Sinovac is a biopharmaceutical company that engages in the research, development, manufacture and commercialization of vaccines against hepatitis A, hepatitis B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps in the People's Republic of China.
On December 21, 2016, media outlet SeekingAlpha issued a report disclosing that Sinovac’s Chairman and CEO, Weidong Ying, had paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, to help procure and pass drug applications and evaluations.
If you purchased Sinovac securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.